{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:00:54Z","timestamp":1761166854525,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.pupt.2020.101988","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T09:19:33Z","timestamp":1609665573000},"page":"101988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["TPMT and HLA-DQA1-HLA-DRB genetic profiling to guide the use of azathioprine in the treatment of interstitial lung disease: First experience"],"prefix":"10.1016","volume":"66","author":[{"given":"Nada","family":"Taha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karishma","family":"Hosein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Grant-Orser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammy","family":"Lin-Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Mura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.pupt.2020.101988_bib1","first-page":"v1","article-title":"Interstitial lung disease guideline: the British thoracic society in collaboration with the thoracic society of Australia and New Zealand and the Irish thoracic society","volume":"63","author":"Bradley","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2020.101988_bib2","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1378\/chest.12-0741","article-title":"Diagnosis and treatment of connective tissue disease-associated interstitial lung disease","volume":"143","author":"Vij","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2020.101988_bib3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4046\/trd.2018.0092","article-title":"Korean guidelines for diagnosis and management of interstitial lung diseases: Part 3. Idiopathic nonspecific interstitial pneumonia","volume":"82","author":"Lee","year":"2019","journal-title":"Tuberc. Respir. Dis."},{"key":"10.1016\/j.pupt.2020.101988_bib4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.5858\/arpa.2016-0299-SA","article-title":"Diagnostic approach to advanced fibrotic interstitial lung disease bringing together clinical, radiologic, and histologic clues","volume":"141","author":"Larsen","year":"2017","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.pupt.2020.101988_bib5","doi-asserted-by":"crossref","first-page":"e1S","DOI":"10.1378\/chest.12-1044","article-title":"Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"142","author":"Baughman","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2020.101988_bib6","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2020.101988_bib7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pupt.2020.101988_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pupt.2019.03.012","article-title":"Implementing an interstitial lung disease clinic improves survival without increasing health care resource utilization","volume":"56","author":"Povitz","year":"2019","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2020.101988_bib9","first-page":"613","article-title":"Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy","volume":"25","author":"Paone","year":"2007","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.pupt.2020.101988_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2020.101988_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.chest.2016.10.029","article-title":"Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis","volume":"151","author":"Morisset","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2020.101988_bib12","doi-asserted-by":"crossref","first-page":"101878","DOI":"10.1016\/j.pupt.2019.101878","article-title":"Impact of azathioprine use in chronic hypersensitivity pneumonitis patients","volume":"60","author":"Terras Alexandre","year":"2020","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2020.101988_bib13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1183\/09031936.99.14511179","article-title":"Treatment of chronic sarcoidosis with an azathioprine\/prednisolone regimen","volume":"14","author":"M\u00fcller-Quernheim","year":"1999","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2020.101988_bib14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1532-5415.2003.51126.x","article-title":"Azathioprine and low-dose corticosteroids for the treatment of cryptogenic organizing pneumonia in an older patient","volume":"51","author":"Laszlo","year":"2003","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.pupt.2020.101988_bib15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1378\/chest.109.5.1397","article-title":"Azathioprine as a steroid-sparing agent in radiation pneumonitis","volume":"109","author":"McCarty","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2020.101988_bib16","first-page":"371","article-title":"Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease","volume":"28","author":"Marshall","year":"2014","journal-title":"Chin. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.pupt.2020.101988_bib17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.gastro.2015.06.002","article-title":"Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease","volume":"149","author":"Coenen","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pupt.2020.101988_bib18","first-page":"26","article-title":"Genetic predictors of azathioprine toxicity and clinical response","volume":"23","author":"Al-Judaibi","year":"2016"},{"key":"10.1016\/j.pupt.2020.101988_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2010.320","article-title":"Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing","volume":"89","author":"Relling","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2020.101988_bib20","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/FPC.0b013e3283097328","article-title":"Functional characterization of 23 allelic variants of .thiopurine S-methyltransferase gene (TPMT*2 - *24)","volume":"18","author":"Ujiie","year":"2008","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.pupt.2020.101988_bib21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bcp.2008.05.009","article-title":"Characterisation of novel defective thiopurine S-methyltransferase allelic variants","volume":"76","author":"Garat","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pupt.2020.101988_bib22","doi-asserted-by":"crossref","first-page":"608","DOI":"10.7326\/0003-4819-126-8-199704150-00003","article-title":"Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance","volume":"126","author":"Yates","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pupt.2020.101988_bib23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/01.fpc.0000114745.08559.db","article-title":"Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-caucasians and identification of novel TPMT variants","volume":"14","author":"Schaeffeler","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.pupt.2020.101988_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/gut.48.5.591","article-title":"Rational dosing of azathioprine and 6-mercaptopurin","volume":"48","author":"Sandborn","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.pupt.2020.101988_bib25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial","volume":"367","author":"Meggitt","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2020.101988_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ecco-jcc\/jjv188","article-title":"Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases-a prospective study on incidence and severity","volume":"10","author":"Teich","year":"2016","journal-title":"J Crohn\u2019s Colitis"},{"key":"10.1016\/j.pupt.2020.101988_bib27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.3093","article-title":"HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants","volume":"46","author":"Heap","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.pupt.2020.101988_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/tpj.2014.47","article-title":"Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: a systematic review of clinical guidance documents","volume":"14","author":"Burnett","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.pupt.2020.101988_bib29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/apt.14483","article-title":"HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease","volume":"47","author":"Wilson","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2020.101988_bib30","article-title":"Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease","volume":"13","author":"Sluiter","year":"2019","journal-title":"J Chrons Colitis"},{"key":"10.1016\/j.pupt.2020.101988_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00408-009-9217-8","article-title":"Thiopurine S-Methyltranferase testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis","volume":"188","author":"Hagaman","year":"2010","journal-title":"Lung"},{"key":"10.1016\/j.pupt.2020.101988_bib32","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2020.101988_bib33","first-page":"5","article-title":"Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients","volume":"6","author":"Sebastiani","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.pupt.2020.101988_bib34","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/j.1572-0241.2008.01848.x","article-title":"Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review","volume":"103","author":"Gisbert","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.pupt.2020.101988_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2036.2003.01690.x","article-title":"Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease","volume":"18","author":"Gearry","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2020.101988_bib36","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1053\/gast.2002.32124","article-title":"Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity","volume":"122","author":"McGovern","year":"2002","journal-title":"Gastroenterology"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553920301930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553920301930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:30:48Z","timestamp":1761082248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553920301930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":36,"alternative-id":["S1094553920301930"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101988","relation":{},"ISSN":["1094-5539"],"issn-type":[{"type":"print","value":"1094-5539"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TPMT and HLA-DQA1-HLA-DRB genetic profiling to guide the use of azathioprine in the treatment of interstitial lung disease: First experience","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101988"}}